1. |
Yang L. Incidence and mortality of gastric cancer in China[J]. World J Gastroenterol, 2006, 12(1):17-20.
|
2. |
Wang YD, Wu P, Mao JD, et al. Relationship between vascular invasion and microvessel density and micrometastasis[J]. World J Gastroenterol, 2007, 13(46):6269-6273.
|
3. |
Zerbini G, Lorenzi M, Palini A. Tumor angiogenesis[J]. Engl J Med, 2008, 359(7):763-764. doi:10.1056/NEJMc081278.
|
4. |
Cook KM, Figg WD. Angiogenesis inhibitors:current strategies and future prospects[J]. CA Cancer J Clin, 2010, 60(4):222-243.
|
5. |
Gadbail AR, Mankar Gadbail MP, Hande A, et al. Tumor angiogenesis:role in locally aggressive biological behavior of amelobla-stoma and keratocystic odontogenic tumor[J]. Head Neck, 2013,.
|
6. |
Lawler PR, Lawler J. Molecular basis for the regulation of angio-genesis by thrombospondin-1 and -2[J]. Cold Spring Harb Pers-pect Med, 2012, 2(5):a006627. doi:10.1101/cshperspect. a00-.
|
7. |
Ribatti D. The crucial role of vascular permeability factor/vascular endothelial growth factor in angiogenesis:a historical review[J]. Br J Haematol, 2005, 128(3):303-309.
|
8. |
Miyato H, Kitayama J, Ishigami H, et al. Loss of sympathetic nerve fibers around intratumoral arterioles reflects malignant potential of gastric cancer[J]. Ann Surg Oncol, 2011, 18(8):2281-2288.
|
9. |
Iordache S, Saftoiu A, Georgescu CV, et al. Vascular endothe-lial growth factor expression and microvessel density—two usefultools for the assessment of prognosis and survival in gastric cancer patients[J]. J Gastrointestin Liver Dis, 2010, 19(2):135-139.
|
10. |
Makrilia N, Lappa T, Xyla V, et al. The role of angiogenesis in solid tumours:an overview[J]. Eur J Intern Med, 2009, 20(7):663-671.
|
11. |
Muhammadnejad S, Muhammadnejad A, Haddadi M, et al. Correlation of microvessel density with nuclear pleomorphism, mitotic count and vascular invasion in breast and prostate cancers at preclinical and clinical levels[J]. Asian Pac J Cancer Prev, 2013, 14(1):63-68.
|
12. |
Nadkarni NJ, Geest KD, Neff T, et al. Microvessel density and p53 mutations in advanced-stage epithelial ovarian cancer[J]. Cancer Lett, 2013, 331(1):99-104.
|
13. |
Jiménez B, Volpert OV, Crawford SE, et al. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1[J]. Nat Med, 2000, 6(1):41-48.
|
14. |
Fleitas T, Martinez-Sales V, Vila V, et al. VEGF and TSP1 levelscorrelate with prognosis in advanced non-small cell lung cancer. Clinical & translational oncology:official publication of the Fede-ration of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2013. doi:10.1007/s12094-013-1020-6.
|
15. |
Armstrong LC, Bornstein P. Thrombospondins 1 and 2 function as inhibitors of angiogenesis[J]. Matrix Biol, 2003, 22(1):63-71.
|
16. |
Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002[J]. CA Cancer J Clin, 2005, 55(2):74-108.
|
17. |
Fontana A, Filleur S, Guglielmi J, et al. Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo[J]. Int J Cancer, 2005, 116(5):686-691.
|
18. |
Firlej V, Mathieu JR, Gilbert C, et al. Thrombospondin-1 triggerscell migration and development of advanced prostate tumors[J]. Cancer Res, 2011, 71(24):7649-7658.
|
19. |
Nakao T, Kurita N, Komatsu M, et al. Expression of thrombos-pondin-1 and Ski are prognostic factors in advanced gastric cancer[J]. Int J Clin Oncol, 2011, 16(2):145-152.
|
20. |
文卫, 杨连粤, 黄耿文, 等. TSP-1和VEGF在肝细胞癌新生血管生成中的作用[J]. 中华肝胆外科杂志, 2005, 11(1):17-19.
|
21. |
Jiang M, Mou CZ, Han T, et al. Thrombospondin-1 and transforming growth factor-β1 levels in prolactinoma and their clinical significance[J]. J Int Med Res, 2012, 40(4):1284-1294.
|
22. |
王蓓, 吕成余, 谢洪虎. 351例胃癌术后患者的预后因素分析[J]. 中国普外基础与临床杂志, 2012, 19(7):743-748.
|
23. |
Zhang J, Ito R, Oue N, et al. Expression of thrombospondin-1 is correlated with microvessel density in gastric carcinoma[J]. Virchows Arch, 2003, 442(6):563-568.
|
24. |
Hippo Y, Yashiro M, Ishii M, et al. Differential gene expression profiles of scirrhous gastric cancer cells with high metastatic potential to peritoneum or lymph nodes[J]. Cancer Res, 2001, 61(3):889-895.
|
25. |
Bilous M, Osamura RY, Rüschoff J, et al. HER-2 amplification is highly homogenous in gastric cancer[J]. Hum Pathol, 2010, 41(2):304-306.
|
26. |
Marx AH, Tharun L, Muth J, et al. HER-2 amplification is highlyhomogenous in gastric cancer[J]. Hum Pathol, 2009, 40(6):769-777.
|
27. |
Negri FV, Bozzetti C, Ardizzoni A, et al. HER-2 discordance between primary gastric carcinoma and paired lymph node metastasis[J]. Hum Pathol, 2011, 42(6):909-910.
|
28. |
Zidan J, Dashkovsky I, Stayerman C, et al. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease[J]. Br J Cancer, 2005, 93(5):552-556.
|
29. |
Kim JH, Kim MA, Lee HS, et al. Comparative analysis of protein expressions in primary and metastatic gastric carcinomas[J]. Hum Pathol, 2009, 40(3):314-322.
|
30. |
Byrne GJ, Hayden KE, McDowell G, et al. Angiogenic characteristics of circulating and tumoural thrombospondin-1 in breast cancer[J]. Int J Oncol, 2007, 31(5):1127-1132.
|
31. |
(3):329-334.
|
32. |
.
|